Crowdonomics
All companies

iRemedy Healthcare

Operating

iRemedy Healthcare Companies

Healthcare · Founded 2007

Solving the pain of today's medical supply chain with artifial intelligence

Estimated pre-money ⓘ
$298.9M
As of Sep 2022 · from Reg A Offering (2022) · our estimate: offering price × shares outstanding, not a stated valuation
Total raised
$3,806,081
Crowd $238K · Private $3.6M · 3 rounds since 2016
Latest share price
$8.50
Reg A+ · Equity · Sep 2022 offering price

Financials

FY2021–FY2023 · from SEC filings · hover any figure for its source
$86.2M
−$14.8M
2021
$52.3M
2022
$2.4M
2023
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2021 audited
FY2022 audited
FY2023 audited
Income statement
Revenue
$86,151,192
$52,253,265
$2,446,719
Cost of goods sold
$72,921,600
$49,786,787
$2,172,821
Gross margin
15%
5%
11%
Net income
-$14,847,660
—
—
Balance sheet
Cash
$561,048
$1,086,226
$111,785
Accounts receivable
$226,428
—
—
Total assets
$25,390,782
—
—
Long-term debt
$776,366
—
—
Total liabilities
$56,452,283
—
—
Other
Headcount
24
—
—

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$298.9M
est. pre-money
Reg A+ · Equity · Sep 2022

Dotted grey bars are our estimate for rounds that didn't state one: the round's share price × the shares outstanding in its filings. Same measure as blue, but rougher.

Cap table

Share counts as of Feb 1, 2023
ClassOutstandingVotes / shareShare of totalLast price
Common Stock35,164,858—100.0%$8.50Sep 2022

Principal holders% as the filing states it, Feb 1, 2023

  • Shareholders iRemedy Investor Group, LLC5,258,341 shares14.8%of company
  • Gary Paquin4,513,201 shares12.8%of company
  • Jim Harding1,900,000 shares5.37%of company
  • Kelly McCarthy1,100,000 shares3.11%of company
  • Kevin Cheung300,000 shares0.85%of company
  • Everyone else (not named in filings)63.1%

Sold to the crowd

From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.

Fundraising history

Reg A+ · Equity · Sep 2022Closedvia Dalmore Group, LLC/OpenDeal Broker LLC
Raised $237.8K / $25MInvestors 149Est. pre-money $298.9M
Raised $3.6MInvestors 53

Team

5 people
Anthony (Tony) Paquin
Chairman of the Board, President and CEO
Gary Paquin
Executive Vice President and Director
Jim Harding
Chief Technology Officer
Kevin Cheung
Chief Financial Officer
Kelly McCarthy
Independent Director

Names and titles as disclosed on SEC Form 1-A. Bios and photos come from the platform campaign page and may be out of date.

  • Form 1-KFeb 18, 20250001493152-25-007014
    EDGAR
  • Form 1-KFeb 7, 20250001493152-25-005355
    EDGAR
  • Form 1-SAFeb 7, 20250001493152-25-005356
    EDGAR
  • Form DJul 31, 20240001903596-24-000445
    EDGAR
  • Form 1-UApr 13, 20230001903596-23-000301
    EDGAR
  • Form 253G1Feb 14, 20230001903596-23-000130
    EDGAR
  • Form QUALIFFeb 13, 20239999999994-23-000063
    EDGAR
  • Form 1-A/AFeb 1, 20230001903596-23-000098
    EDGAR
Source: ManualCIK 0001691249Share price $8.50

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.